Skip to main content
Article thumbnail
Location of Repository

826 Notices to Readers Update: Staphylococcus aureus with Reduced Susceptibility

By  and To Vancomycin United States and To Vancomycin United States


Staphylococcus aureus is one of the most common causes of both hospitaland community-acquired infection worldwide. Since the emergence of methicillinresistant S. aureus (MRSA) in the 1980s in the United States, vancomycin has been the antimicrobial agent of choice for serious MRSA infections. S. aureus with reduced susceptibility to vancomycin (minimum inhibitory concentration [MIC]=8 µ/mL) was first reported to have caused infection in a patient in Japan in May 1996 (1). In August 1997, the first S. aureus isolate intermediately resistant to vancomycin (VISA; MIC=8 µ/mL) in the United States was reported in Michigan (2). This report updates the ongoing investigation in Michigan and describes preliminary findings of the ongoing investigation of a second case of VISA infection in a patient in New Jersey. Case 1. In July 1997, VISA-associated peritonitis was diagnosed in a Michigan resident who was being treated with long-term ambulatory peritoneal dialysis (2). During January–June, the patient had been treated with multiple courses of both intraperitoneal and intravenous vancomycin for repeated episodes of vancomycinsusceptible, MRSA-associated peritonitis. Although intermediately resistant to vancomycin

Year: 1997
OAI identifier: oai:CiteSeerX.psu:
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.